PMA P150013S023

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S023
Product code
PLS
Decision date
2021-11-23
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Approval order statement
Approved the removal of the urothelial carcinoma (UC) indication from the device intended use statement and labeling.

Current openFDA PMA Record#

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S023
Product code
PLS
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Decision date
2021-11-23
Decision code
APPR
Date received
2021-11-17
Supplement type
Special (Immediate Track)
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approved the removal of the urothelial carcinoma (UC) indication from the device intended use statement and labeling.